Find a Trial

Trial Summary


Protocol No.PHO-COG-AALL1821
StatusOPEN TO ACCRUAL
Principal InvestigatorBatra, Sandeep
ScopeNational
PhasePhase II
Age GroupAdults and Children
TitleAALL1821, A Phase 2 Study of Blinatumomab (NSC # 765986, IND # 125462) in Combination with Nivolumab (NSC # 748726, IND # 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged equal to or more than 1 to less than 31 Years Old with First Relapse.
Applicable Disease SitesLymphoid Leukemia
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactSara Quetant, Phone:
    Pager:
    Email: squetant@iu.edu